Annual SG&A
$218.94 M
+$20.57 M+10.37%
31 March 2024
Summary:
Taro Pharmaceutical Industries annual selling, general & administrative expenses is currently $218.94 million, with the most recent change of +$20.57 million (+10.37%) on 31 March 2024. During the last 3 years, it has risen by +$127.58 million (+139.65%).TARO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$58.13 M
+$7.72 M+15.31%
31 March 2024
Summary:
Taro Pharmaceutical Industries quarterly selling, general & administrative expenses is currently $58.13 million, with the most recent change of +$7.72 million (+15.31%) on 31 March 2024. Over the past year, it has increased by +$3.59 million (+6.58%).TARO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
N/A
31 March 2024
Summary:
Taro Pharmaceutical Industries TTM selling, general & administrative expenses is not available.TARO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TARO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.4% | +6.6% | - |
| 3 y3 years | +139.7% | +145.4% | - |
| 5 y5 years | +143.3% | +145.8% | - |
TARO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | at high |
Taro Pharmaceutical Industries Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | $218.94 M(+10.4%) | $58.13 M(+15.3%) | $218.94 M(+3.8%) |
| Dec 2023 | - | $50.41 M(-7.6%) | $210.94 M(+0.3%) |
| Sept 2023 | - | $54.54 M(-2.4%) | $210.39 M(+6.2%) |
| June 2023 | - | $55.86 M(+11.4%) | $198.10 M(-0.1%) |
| Mar 2023 | $198.37 M(+74.5%) | $50.13 M(+0.5%) | $198.37 M(+4.7%) |
| Dec 2022 | - | $49.86 M(+18.0%) | $189.41 M(+15.2%) |
| Sept 2022 | - | $42.26 M(-24.7%) | $164.39 M(+12.7%) |
| June 2022 | - | $56.12 M(+36.3%) | $145.82 M(+28.3%) |
| Mar 2022 | $113.68 M(+24.4%) | $41.18 M(+65.8%) | $113.68 M(+20.0%) |
| Dec 2021 | - | $24.84 M(+4.9%) | $94.73 M(+2.2%) |
| Sept 2021 | - | $23.68 M(-1.2%) | $92.69 M(-0.4%) |
| June 2021 | - | $23.98 M(+7.8%) | $93.08 M(+1.9%) |
| Mar 2021 | $91.36 M(-2.2%) | $22.23 M(-2.5%) | $91.35 M(-7.0%) |
| Dec 2020 | - | $22.80 M(-5.3%) | $98.23 M(+1.9%) |
| Sept 2020 | - | $24.07 M(+8.2%) | $96.36 M(+0.4%) |
| June 2020 | - | $22.25 M(-23.6%) | $95.94 M(+2.7%) |
| Mar 2020 | $93.41 M(+3.8%) | $29.11 M(+39.1%) | $93.41 M(+6.6%) |
| Dec 2019 | - | $20.93 M(-11.5%) | $87.62 M(-3.3%) |
| Sept 2019 | - | $23.65 M(+20.0%) | $90.57 M(+5.2%) |
| June 2019 | - | $19.72 M(-15.4%) | $86.11 M(-4.3%) |
| Mar 2019 | $89.97 M(+2.0%) | $23.32 M(-2.4%) | $89.97 M(-0.5%) |
| Dec 2018 | - | $23.88 M(+24.5%) | $90.42 M(+2.3%) |
| Sept 2018 | - | $19.18 M(-18.6%) | $88.37 M(+1.0%) |
| June 2018 | - | $23.58 M(-0.8%) | $87.53 M(-0.8%) |
| Mar 2018 | $88.20 M(+3.0%) | $23.77 M(+8.9%) | $88.20 M(+1.8%) |
| Dec 2017 | - | $21.83 M(+19.0%) | $86.63 M(+1.8%) |
| Sept 2017 | - | $18.34 M(-24.4%) | $85.11 M(-2.9%) |
| June 2017 | - | $24.25 M(+9.2%) | $87.65 M(+2.3%) |
| Mar 2017 | $85.66 M(-7.3%) | $22.21 M(+9.3%) | $85.66 M(-0.4%) |
| Dec 2016 | - | $20.31 M(-2.7%) | $86.01 M(-2.9%) |
| Sept 2016 | - | $20.89 M(-6.1%) | $88.56 M(-3.4%) |
| June 2016 | - | $22.25 M(-1.4%) | $91.72 M(-0.7%) |
| Mar 2016 | $92.36 M(+5.4%) | $22.56 M(-1.3%) | $92.36 M(+0.4%) |
| Dec 2015 | - | $22.87 M(-4.9%) | $92.03 M(+1.7%) |
| Sept 2015 | - | $24.05 M(+5.0%) | $90.51 M(+2.7%) |
| June 2015 | - | $22.89 M(+3.0%) | $88.15 M(+0.6%) |
| Mar 2015 | $87.64 M(-4.5%) | $22.23 M(+4.1%) | $87.64 M(-4.8%) |
| Dec 2014 | - | $21.34 M(-1.6%) | $92.06 M(-0.6%) |
| Sept 2014 | - | $21.68 M(-3.1%) | $92.62 M(-0.6%) |
| June 2014 | - | $22.39 M(-16.0%) | $93.17 M(+1.6%) |
| Mar 2014 | $91.73 M(+6.1%) | $26.65 M(+21.7%) | $91.73 M(+5.2%) |
| Dec 2013 | - | $21.90 M(-1.5%) | $87.21 M(+1.3%) |
| Sept 2013 | - | $22.23 M(+6.1%) | $86.06 M(+2.7%) |
| June 2013 | - | $20.95 M(-5.3%) | $83.81 M(+0.8%) |
| Mar 2013 | $86.44 M(+274.2%) | $22.13 M(+6.6%) | $83.14 M(-1.2%) |
| Dec 2012 | - | $20.75 M(+3.9%) | $84.11 M(-1.4%) |
| Sept 2012 | - | $19.98 M(-1.5%) | $85.29 M(-5.0%) |
| June 2012 | - | $20.28 M(-12.2%) | $89.75 M(-5.1%) |
| Mar 2012 | $23.10 M(-75.4%) | $23.10 M(+5.3%) | $94.56 M(+0.7%) |
| Dec 2011 | $93.92 M(-13.0%) | $21.93 M(-10.3%) | $93.92 M(-6.2%) |
| Sept 2011 | - | $24.44 M(-2.6%) | $100.11 M(-3.1%) |
| June 2011 | - | $25.09 M(+11.7%) | $103.36 M(-2.0%) |
| Mar 2011 | - | $22.46 M(-20.1%) | $105.46 M(-2.3%) |
| Dec 2010 | $107.90 M(+7.5%) | $28.12 M(+1.6%) | $107.90 M(+5.0%) |
| Sept 2010 | - | $27.68 M(+1.8%) | $102.78 M(+1.7%) |
| June 2010 | - | $27.20 M(+9.2%) | $101.10 M(-0.5%) |
| Mar 2010 | - | $24.90 M(+8.2%) | $101.58 M(+1.2%) |
| Dec 2009 | $100.34 M | $23.00 M(-11.5%) | $100.34 M(-7.2%) |
| Sept 2009 | - | $26.00 M(-6.0%) | $108.09 M(+1.6%) |
| June 2009 | - | $27.68 M(+16.9%) | $106.38 M(+3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2009 | - | $23.66 M(-23.0%) | $102.51 M(+30.0%) |
| Dec 2008 | $99.03 M(+1.8%) | $30.75 M(+26.6%) | $78.84 M(+63.9%) |
| Sept 2008 | - | $24.29 M(+2.1%) | $48.09 M(+102.1%) |
| June 2008 | - | $23.80 M(-38.5%) | $23.80 M(-78.5%) |
| Dec 2007 | $97.27 M(-10.8%) | - | - |
| Dec 2006 | $109.05 M(-1.5%) | - | - |
| Dec 2005 | $110.75 M(-10.2%) | $38.69 M(+73.4%) | $110.75 M(+9.6%) |
| Sept 2005 | - | $22.32 M(-4.3%) | $101.01 M(-6.7%) |
| June 2005 | - | $23.32 M(-11.7%) | $108.31 M(-6.3%) |
| Mar 2005 | - | $26.42 M(-8.7%) | $115.57 M(-6.3%) |
| Dec 2004 | $123.30 M(+26.2%) | $28.95 M(-2.3%) | $123.30 M(-2.5%) |
| Sept 2004 | - | $29.63 M(-3.1%) | $126.45 M(+3.2%) |
| June 2004 | - | $30.57 M(-10.5%) | $122.50 M(+7.1%) |
| Mar 2004 | - | $34.15 M(+6.4%) | $114.33 M(+17.0%) |
| Dec 2003 | $97.72 M(+86.2%) | $32.10 M(+25.0%) | $97.72 M(+21.2%) |
| Sept 2003 | - | $25.68 M(+14.6%) | $80.64 M(+18.5%) |
| June 2003 | - | $22.40 M(+27.7%) | $68.03 M(+16.7%) |
| Mar 2003 | - | $17.54 M(+16.8%) | $58.28 M(+11.0%) |
| Dec 2002 | $52.48 M(+24.7%) | $15.02 M(+15.0%) | $52.48 M(+9.3%) |
| Sept 2002 | - | $13.07 M(+3.3%) | $48.01 M(+3.8%) |
| June 2002 | - | $12.65 M(+7.7%) | $46.23 M(+2.7%) |
| Mar 2002 | - | $11.74 M(+11.3%) | $45.01 M(+7.0%) |
| Dec 2001 | $42.09 M(+31.9%) | $10.55 M(-6.6%) | $42.09 M(+3.9%) |
| Sept 2001 | - | $11.29 M(-1.3%) | $40.52 M(+8.2%) |
| June 2001 | - | $11.43 M(+29.6%) | $37.45 M(+10.3%) |
| Mar 2001 | - | $8.82 M(-1.8%) | $33.96 M(+6.5%) |
| Dec 2000 | $31.90 M(+23.0%) | $8.98 M(+9.2%) | $31.90 M(+3.7%) |
| Sept 2000 | - | $8.22 M(+3.5%) | $30.76 M(+6.3%) |
| June 2000 | - | $7.94 M(+17.6%) | $28.93 M(+6.4%) |
| Mar 2000 | - | $6.76 M(-13.7%) | $27.19 M(+4.8%) |
| Dec 1999 | $25.93 M(+25.3%) | $7.83 M(+22.4%) | $25.93 M(+43.3%) |
| Sept 1999 | - | $6.40 M(+3.2%) | $18.10 M(+54.7%) |
| June 1999 | - | $6.20 M(+12.7%) | $11.70 M(+112.7%) |
| Mar 1999 | - | $5.50 M(+19.6%) | $5.50 M(-69.6%) |
| Dec 1998 | $20.70 M(+15.0%) | - | - |
| Mar 1998 | - | $4.60 M(0.0%) | $18.10 M(+1.1%) |
| Dec 1997 | $18.00 M(+1.7%) | $4.60 M(+2.2%) | $17.90 M(+0.6%) |
| Sept 1997 | - | $4.50 M(+2.3%) | $17.80 M(0.0%) |
| June 1997 | - | $4.40 M(0.0%) | $17.80 M(-0.6%) |
| Mar 1997 | - | $4.40 M(-2.2%) | $17.90 M(0.0%) |
| Dec 1996 | $17.70 M(-24.4%) | $4.50 M(0.0%) | $17.90 M(+33.6%) |
| Sept 1996 | - | $4.50 M(0.0%) | $13.40 M(+50.6%) |
| June 1996 | - | $4.50 M(+2.3%) | $8.90 M(+102.3%) |
| Mar 1996 | - | $4.40 M(+18.9%) | $4.40 M(-62.1%) |
| Dec 1995 | $23.40 M(+30.7%) | - | - |
| Dec 1994 | $17.90 M(+31.6%) | - | - |
| Dec 1993 | $13.60 M(+16.2%) | - | - |
| Dec 1992 | $11.70 M(+51.9%) | $3.70 M(+32.1%) | $11.60 M(+19.6%) |
| Sept 1992 | - | $2.80 M(-3.4%) | $9.70 M(+9.0%) |
| June 1992 | - | $2.90 M(+31.8%) | $8.90 M(+11.3%) |
| Mar 1992 | - | $2.20 M(+22.2%) | $8.00 M(+3.9%) |
| Dec 1991 | $7.70 M(+51.0%) | $1.80 M(-10.0%) | $7.70 M(+30.5%) |
| Sept 1991 | - | $2.00 M(0.0%) | $5.90 M(+51.3%) |
| June 1991 | - | $2.00 M(+5.3%) | $3.90 M(+105.3%) |
| Mar 1991 | - | $1.90 M(+35.7%) | $1.90 M(+35.7%) |
| Dec 1990 | $5.10 M(+8.5%) | - | - |
| Mar 1990 | - | $1.40 M | $1.40 M |
| Dec 1989 | $4.70 M(+34.3%) | - | - |
| Dec 1988 | $3.50 M(0.0%) | - | - |
| Dec 1987 | $3.50 M | - | - |
FAQ
- What is Taro Pharmaceutical Industries annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Taro Pharmaceutical Industries?
- What is Taro Pharmaceutical Industries annual SG&A year-on-year change?
- What is Taro Pharmaceutical Industries quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Taro Pharmaceutical Industries?
- What is Taro Pharmaceutical Industries quarterly SG&A year-on-year change?
- What is the all time high TTM SG&A for Taro Pharmaceutical Industries?
What is Taro Pharmaceutical Industries annual selling, general & administrative expenses?
The current annual SG&A of TARO is $218.94 M
What is the all time high annual SG&A for Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries all-time high annual selling, general & administrative expenses is $218.94 M
What is Taro Pharmaceutical Industries annual SG&A year-on-year change?
Over the past year, TARO annual selling, general & administrative expenses has changed by +$20.57 M (+10.37%)
What is Taro Pharmaceutical Industries quarterly selling, general & administrative expenses?
The current quarterly SG&A of TARO is $58.13 M
What is the all time high quarterly SG&A for Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries all-time high quarterly selling, general & administrative expenses is $58.13 M
What is Taro Pharmaceutical Industries quarterly SG&A year-on-year change?
Over the past year, TARO quarterly selling, general & administrative expenses has changed by +$3.59 M (+6.58%)
What is the all time high TTM SG&A for Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries all-time high TTM selling, general & administrative expenses is $218.94 M